The world faces an epidemic of atrial fibrillation and atrial fibrillation-related stroke. An
individual's risk of atrial fibrillation-related stroke can be estimated with the CHADS 2 or CHA …

Objective We performed a systematic review and meta-analysis to compare the risk of
intracranial hemorrhage (ICH) between direct oral anticoagulants (DOACs) and other …

The increasing use of antithrombotic drugs in an aging population [including anticoagulants
to prevent future ischemic stroke in individuals with atrial fibrillation (AF)] has been …

Background and Purpose: It is unknown when to start anticoagulation after acute ischemic
stroke (AIS) from atrial fibrillation (AF). Early anticoagulation may prevent recurrent …

Background and aims Documentation of atrial fibrillation is required to initiate oral
anticoagulation therapy for recurrent stroke prevention. Atrial fibrillation often goes …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Abstract Purpose of Review: Cardioembolic stroke is common and disproportionately more
disabling than nonembolic mechanisms of stroke. Its incidence is expected to rise because …

Purpose Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all
risk stratification schemes. A systematic review and meta-analysis was performed to …

The aims of this article are to review the evidence regarding the use of non-vitamin K oral
anticoagulants (NOACs) for secondary stroke prevention as compared to vitamin K …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …